The ACTN3 R577X polymorphism affects the lipid profile and the prognosis of nutritional intervention in HIV-positive patients

The hypothesis of the present study is that the polymorphisms in the APOC3, CEPT, ACE, and ACTN3 genes can affect the outcome of nutritional intervention and the plasma lipid profile of HIV+ patients. To test the hypothesis, genetic material was collected from buccal cells, and serum was collected for biochemical analysis. Sixty-five patients were analyzed. The incorporation of protease inhibitor (PI) was more frequent in women (77% vs 33% in men). Nutritional intervention improved anthropometric parameters independent of the genotype. Patients with the RR genotype for the ACTN3 R577X polymorphism had lower glycemia (RR = 95.4 +/- 6.5 mg/dL, RX = 102.6 +/- 10.6 mg/dL, XX = 110.1 +/- 16.3 mg/dL; P = .03) and a greater reduction in low-density lipoproteins (LDL) after intervention (LDL: RR = -23.7 +/- 15.8 mg/dL, RX = 1.32 +/- 5.13 mg/dL, XX = 30.21 +/- 24.4 mg/dL; P = .01). Patients using PI had a negative response to dietary intervention regarding the levels of high-density lipoprotein (-2.4 +/- 1.70 with PI, 2.56 +/- 1.60 mg/dL without PI; P = .02), very low density lipoprotein (0.84 +/- 2.73 with IP, -5.46 +/- 3.37 mg/dL without PI; P = .03), and triglycerides (1.79 +/- 13.22 with PI, -34.00 +/- 17.67 mg/dL without PI; P = .052). This response was also independent of the genotype (P > 0.05) and suggested the need for oral lipid-lowering drugs in all HIV+ patients using PI. Our results indicate that the ACTN3 R577X polymorphism is a good predictor of both the lipid profile and the prognosis of nutritional intervention in reducing LDL in HIV+ patients. (C) 2016 Elsevier Inc. All rights reserved.